Is travel prophylaxis worth while ? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers.
To estimate the costs and benefits of prophylaxis against travel acquired malaria, typhoid fever, and hepatitis A in United Kingdom residents during 1991.
Design-Retrospective analysis of national epidemiological and economic data.
Main outcome measures-Incidence of travel associated infections in susceptible United Kingdom residents per visit ; costs of prophylaxis provision from historical data ; benefits to the health sector, community, and individuals in terms of avoided morbidity and mortality based on hospital and community costs of disease.
The high incidence of imported malaria (0.70%) and the low costs of providing chemoprophylaxis resulted in a cost-benefit ratio of 0.19 for chloroquine and proguanil and 0.57 for a regimen containing mefloquine.
Mots-clés Pascal : Maladie d'importation, Paludisme, Protozoose, Infection, Hépatite virale A, Virose, Appareil digestif pathologie, Foie pathologie, Homme, Thyroïde, Prévention, Coût, Economie santé, Immunoprophylaxie
Mots-clés Pascal anglais : Imported disease, Malaria, Protozoal disease, Infection, Viral hepatitis A, Viral disease, Digestive diseases, Hepatic disease, Human, Thyroid gland, Prevention, Costs, Health economy, Immunoprophylaxis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0704689
Code Inist : 002B05A02. Création : 09/06/1995.